Peer-reviewedCC BY-NC-NDEJHaem
Aplastic Anaemia in a Chronic Lymphocytic Leukaemia Patient Treated With Acalabrutinib, a Bruton Tyrosine Kinase Inhibitor—Case Report
- 1Eastern Health
Related
- Richter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape
- Persistent SARS‐CoV‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report
- USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival.
- Economic Burden of Chronic Lymphocytic Leukaemia in Australia
- Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups
BibTeX
@article{wei2026aplastic,
title = {{Aplastic Anaemia in a Chronic Lymphocytic Leukaemia Patient Treated With Acalabrutinib, a Bruton Tyrosine Kinase Inhibitor—Case Report}},
author = {Zachray Wei and Tamara Marconi and Lucy Tuck and Stephen Ting},
journal = {EJHaem},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13652953},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Aplastic Anaemia in a Chronic Lymphocytic Leukaemia Patient Treated With Acalabrutinib, a Bruton Tyrosine Kinase Inhibitor—Case Report
AU - Zachray Wei
AU - Tamara Marconi
AU - Lucy Tuck
AU - Stephen Ting
PY - 2026
DA - 2026/10/01
JO - EJHaem
UR - https://europepmc.org/article/PMC/PMC13652953
SN - 2688-6146
ER -